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Expression of Id Helix-Loop-Helix Proteins in Colorectal Adenocarcinoma
Correlates with p53 Expression and Mitotic Index1
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ABSTRACT
Id helix-loop-helix (HLH) proteins function as regulators of cell growth
and differentiation and when overexpressed can induce malignant trans-
formation. In a series of 34 cases of primary human colorectal adenocar-
cinoma, immunoreactivity for Id1, Id2, and Id3 was found to be signifi-
cantly elevated in tumor compared with normal mucosa (P 0.001 for Id1
and Id2; P  0.002 for Id3). No elevation of Id expression was observed in
17 cases of adenoma. Expression of Id1 and to a lesser extent of Id2 was
correlated with mitotic index (P  0.005 for Id1; P  0.042 for Id2) in
human adenocarcinomas, and expression of all three Id proteins was
correlated with p53 immunoreactivity (a marker of mutational ‘inactiva-
tion’ of p53 function; P  0.002 for Id1; P  0.006 for Id2; P  0.016 for
Id3). In normal intestinal mucosa of p53-null mice and in spontaneous
tumors arising in Min/ mice, expression of all three Id proteins was
also found to be up-regulated. Antisense oligonucleotide blockade of Id
protein expression inhibited the proliferation of human adenocarcinoma
cells. Enforced, ectopic expression of the E47 basic HLH (bHLH) protein
in human adenocarcinoma cell lines efficiently sequestered endogenous Id
proteins as Id-bHLH heterodimers, as shown by coimmunoprecipitation
and subcellular colocalization studies. This led to growth arrest of the
cells. Enforced overexpression of a mutant E47 protein, deficient in trans-
activation and DNA binding function, also partially inhibited cell growth.
Taken together, these data imply that deregulated expression of Id pro-
teins in colorectal adenocarcinoma arises at least in part as a consequence
of loss of p53 function and contributes to the uncontrolled proliferation of
tumor cells in colorectal cancer.
INTRODUCTION
Members of the Id family of HLH3 proteins play a pivotal role in
the regulation of cell lineage commitment, growth, and differentiation
in most, if not all, mammalian cell lineages (reviewed in Refs. 1–3).
There are four Id family members in mammals (Id1–4). They function
by binding to and antagonizing the activities of several classes of
transcriptional regulator-bHLH proteins (4, 5), Rb “pocket” proteins
(6–8), Ets domain proteins (9), and Pax homeodomain-containing
proteins (10). Of these, heterodimeric interactions with members of
the bHLH protein family (mediated via the HLH domain) are estab-
lished as being functionally the most important (1, 2, 4, 5). Accumu-
lating evidence supports the view that the maintenance of a critical
balance between a cell’s complement of bHLH and Id proteins is
important for cell fate decisions of growth and differentiation; expres-
sion of Id proteins is typically high in actively proliferating cells and
is down-regulated as a prerequisite for exit from the cell cycle and
terminal differentiation (1–3).
Enforced expression of Id genes in a variety of cell types promotes
proliferation (1) and, under appropriate physiological conditions, also
drives apoptosis (11–13). In addition, Id function is required for the
G1 to S-phase transition of the cell cycle (14–16). In common with
several other positive regulators of G1 to S-phase transition, Id genes
function as cooperating oncogenes in the immortalization of primary
cells (11, 17) and will also induce disordered cell growth in fibroblast
and epithelial cell lines (18, 19). More recent data have shown that Id
function is required for vascularization and invasiveness of tumor
growth in vivo (Ref. 20; reviewed in Ref. 2). Moreover, targeted
expression of Id genes in transgenic mice, which typically results in a
differentiation block, has also been shown to cause lymphomas (21,
22) and tumors of the intestinal epithelium (23).
Deregulated expression of Id genes has been described in tumor cell
lines from lung, colon, pancreas, and in both neuronal and astrocytic
tumor lines of the nervous system (reviewed in Ref. 3). A similar
deregulation of Id expression has been reported in some primary
human tumors such as seminomas (24), pancreatic adenocarcinomas
(25, 26), squamous cell carcinomas (27), and mammary tumors (28).
Significantly, high level expression of Id1 has been reported to be
more frequently associated with infiltrating, more aggressive mam-
mary epithelial tumors than with ductal tumors, which suggests a link
between Id expression and disease progression (28). We report here
on a systematic analysis of Id protein expression in primary human
and mouse intestinal tumors. We have found that, compared with most
normal intestinal mucosa, tumor tissues (but not premalignant adeno-
mas) express high levels of the Id1–3 proteins. Id expression is
correlated with mitotic index and with p53 expression level (a marker
of mutational modulation of p53 function) in human colorectal ade-
nocarcinoma. Normal mucosa from p53-null mice displayed increased
expression of Id1–3, and abrogation of Id function in colorectal
adenocarcinoma cell lines by antisense oligonucleotide blockade or by
enforced expression of bHLH protein led to growth arrest. These data
imply that deregulated expression of Id proteins in colorectal cancer
arises in part as a consequence of loss of p53 function and contributes
to the uncontrolled proliferation of this tumor type.
MATERIALS AND METHODS
Patient Samples. Samples were obtained with informed consent from 34
patients undergoing radical surgery for colorectal cancer. All of the patients
were classified according to the Jass (29) and Tumor-Node-Metastasis (TNM)
classifications (30). Tumor ploidy was assessed by flow cytometric determi-
nation of DNA content as described previously (31). Other data for the tumor
series have been reported previously (31).
The human colonic adenocarcinoma cell lines, HCLO (32) and LS174T
(33), were obtained from the American Type Culture Collection and grown in
RPMI 1640 medium supplemented with 10% FCS.
Mouse Tissues. p53-null mice (p53/; Ref. 34) and Min/ mice (35)
were maintained and genotyped as described previously (36). For immunohis-
tochemical analysis, guts were excised, flushed with ice-cold PBS and fixed in
4% formaldehyde in PBS (pH 7.4) overnight at 4°C. Samples were washed
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three times in 70% ethanol before dehydration through graded alcohols and
xylene and were finally embedded in paraffin wax. Sections were cut at 3-m
thickness, dried onto 3-aminopropyl triethoxysilane-coated slides, and stored
at 4°C until use (31).
Antibodies. Mouse anti-p53 IgG (DOH7, M7001) was obtained from Dako
(High Wycombe, United Kingdom). Rabbit anti-p53 IgG (CM5) was a kind
gift from Prof. D. P. Lane (University of Dundee, Dundee, United Kingdom).
Rabbit anti-Id IgG antibodies (Id1, sc-488; Id2, cs-489; and Id3, sc-490) and
anti-E47 rabbit antibody were purchased from Santa Cruz Biotechnology
(Autogen Bioclear, Wilts, United Kingdom). In some experiments, a rabbit
anti-Id3 antibody preparation, RD7 (37), was used. Rabbit anti-LacZ antibody
was purchased from 5 Prime to 3 Prime Inc. Antirabbit secondary antibodies
(biotinylated, FITC-conjugated, or TRITC-conjugated) were obtained from
Dako. Antibody specific to the Myc-epitope tag (9E10) was purchased from
Sigma Life Sciences (Poole, Dorset, United Kingdom).
Immunohistochemistry. Immunohistochemistry was carried out as de-
scribed previously (31). Anti-Id3 IgG was used at 50 ng/ml; anti-Id1 and
anti-Id2 were used at 100 ng/ml and anti-Id4 was used at 200 ng/ml. Mouse
anti-p53 IgG was used at 100 ng/ml, CM5 rabbit anti-p53 IgG was used at a
dilution of 1:20,000. Biotinylated secondary antibody was used at 1200 dilu-
tion. Vector ABC reagents were used in accordance with the manufacturer’s
instructions to amplify immunoreactivity. Final detection used 3–3diamino-
benzidine as the chromogen. Slides were counterstained with thionine and
mounted with XAM permanent mountant. Immunostaining specificity was
rigorously established form trial experiments using homologous and heterol-
ogous blocking peptides as described previously (11, 31).
The staining of sections was quantitated as described previously (31) by
assigning a score out of three for intensity of immunoreactivity (INT) and for
the proportion of (epithelial) cells stained (PROP). The product of these two
values was taken to give the overall total score (TS). Tumor sections were
viewed and evaluated by two independent observers without prior knowledge
of histopathology data (31). Statistical analysis was carried out by using SPSS
for Windows (version 7.5.1; SPSS Inc.). Data were compared using a non-
parametric Kruskal-Wallis test for ANOVA, and a Mann-Whitney test was
used to assess the difference between individual data sets. The level of
significance was determined at P  0.05. Correlations between immuno-
staining data and other variables were assessed by calculating Spearman’s
correlation coefficients.
Immunoprecipitation and Western Blotting. Intestinal tissues were sur-
gically removed and either cryopreserved or lysed directly in RIPA buffer (50
mM NaCl, 25 mM Tris-HCl, pH 8.0, 0.5% NP40, 0.5% sodium deoxycholate,
0.1% SDS). For experiments with cell lines, cells were also lysed in RIPA
buffer for direct immunoprecipitation-Western analysis. However, for coim-
munoprecipitation analysis, cells were lysed in “HB” buffer [0.3 M sucrose, 10
mM Tris-HCl (pH 8.0), 10 mM NaCl, 3 mM MgCl2, and 0.5% NP40]. Both lysis
buffers contained a mixture of protease inhibitors; 0.1 mM phenylmethylsul-
fonyl fluoride; leupeptin, bestatin, and aprotinin (100 g/ml each); and 2 mM
levamisole. For some experiments, intestinal epithelial cells were prepared by
the Weiser method (38). Before Western blotting, Id proteins were initially
subjected to immunoprecipitation from RIPA or HB lysates. This and subse-
quent Western analysis was performed as described previously (24, 37).
Antisense Oligonucleotide Blockade of Id Protein Expression. Unmod-
ified antisense oligonucleotides for each of the Id mRNAs, Id1–3, were
essentially as described in previous studies (14, 16, 25). The sequences were:
Id1, GCGACTTTCATGATTGG; Id2, AGGCTTTCATGCTGACCGC; and
Id3, CAGCGCCTTCATGCTGGGGAG. Oligonucleotides of the correspond-
ing sense sequences were used as controls. After dissolving in 10 mM Tris/0.1
mM EDTA (pH 7.4), the oligonucleotides were added as an equimolar mixture
at various concentrations to subconfluent cultures of cells in 8-well chamber
slides under standard growth conditions. After 17 h, the cells were pulsed for
2 h with BrdUrd and immunostained for BrdUrd by using a commercial kit
(Boehringer) essentially as described by the supplier. A minimum of 300 cells
were scored for each concentration of oligonucleotide used.
Transfection and Immunofluorescence Analysis of Cell Lines. Expres-
sion vectors encoding Id proteins (pcDNA-Id3, pcDNA-Id2, pcDNA-Id1), E47
(pcDNA3E47), and LacZ (pEQ176) have been described previously (11). A
mutant version of E47 (aHLH), defective in both transactivation and DNA-
binding functions (see Fig. 8A in ”Results“) was constructed by PCR mutagen-
esis and inserted into the vector, pcDNA3, by standard recombinant DNA
techniques. The presence of mutations in the basic, DNA-binding region that
have been shown previously to abolish DNA binding (39), were confirmed by
DNA sequencing. Subconfluent cultures of cells in 60-mm dishes were trans-
fected with a total of 8 g of DNA by using the standard calcium phosphate
procedure. Next day, cells were either lysed in HB buffer for immunoprecipi-
tation analysis or else reseeded onto slides for immunofluorescence analysis.
After attachment, cells were fixed and stained for either Id3 (using FITC-
conjugated secondary antibody) or E47 (using TRITC-conjugated secondary
antibody) and counterstained with DAPI, as described previously (11, 37). In
separate experiments, cells on slides were pulsed for 2 h with BrdUrd and then
fixed and immunostained for LacZ; BrdUrd was then incorporated by using a
commercial kit (Boehringer) according to the manufacturer’s instructions.
Slides were finally mounted in Vectashield mountant containing DAPI and
evaluated by fluorescence microscopy. For quantitative analysis, a minimum
of 200 LacZ-positive cells were evaluated for each transfection.
RESULTS
Expression of Id Proteins in Normal and Tumor Tissue from
Human Colonic Epithelium. Immunostaining of normal human co-
lonic epithelium revealed low but detectable expression of Id1, Id2,
and Id3 protein as illustrated in Fig. 1A. No significant staining for Id4
was detected (data not shown). The specificity of immunoreactivity
for each Id antibody was established in control experiments using
homologous/heterologous peptide competition and preimmune sera,
as reported previously (Ref. 9; data not shown). The pattern of
staining for each Id protein in normal human colonic mucosa (Fig. 1A)
was broadly similar to that previously reported for the small intestine
in mouse (23). Immunoreactivity was observed primarily in the upper
third of the colonic crypts and in the table region between the tops of
the crypts. The staining for Id1 and Id2 was mostly cytoplasmic,
whereas that for Id3 was predominantly nuclear.
A panel of 34 well-characterized human colorectal adenocarcino-
mas was screened by immunohistochemistry with each of the four Id
antibodies. With the exception of Id4, which, as in normal intestinal
epithelium, was not significantly expressed in tumor tissue, all of the
Id proteins were expressed at higher levels in tumor versus normal
Fig. 1. Expression of Id proteins in human adenocarcinoma. A, immunostaining of
representative sections from normal and tumor (T1, T2) colonic epithelia. B, Western
analysis of immunoprecipitates of Id protein from three primary colonic adenocarcinomas
(T1–T3) compared with normal colonic epithelium (N).
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tissue. Fig. 1A illustrates typical staining for a representative tumor
compared with normal mucosa from the same patient; and in Fig. 1B,
three tumors are compared with normal mucosal epithelium by West-
ern analysis. Fig. 2 summarizes the quantitative data comparing
immunoreactivity of tumor and normal mucosa for all 34 patients. The
elevated expression of Id1, Id2 and Id3 in tumor compared with
normal tissue was statistically significant (P  0.001 for Id1 and Id2;
P  0.002 for Id3; Wilcoxon signed rank test) for the patient series as
a whole (Fig. 2). Despite the overall increase in tumor-associated Id
immunoreactivity, there was considerable heterogeneity both in the
proportion of tumor cells staining, the intensity of staining, and,
particularly for Id3, the nuclear-cytoplasmic distribution of Id staining
(Fig. 2). By contrast, mucosal samples displayed a narrower range of
immunoreactivity. Interestingly, three mucosal specimens (A, B, and
C in Fig. 2) were exceptional and gave consistently high immunore-
activity scores for different Ids. When the data for the patient series
was further evaluated, we found no relationship between the profile of
Id protein staining and tumor histotype, node involvement, ploidy,
sex, or expression of the Bcl-2 family proteins, Bcl-w and Bcl-2 (data
not shown). However, as shown in Table 1, there was a significant
association between tumor stage and Id2 staining, with Jass stage IV
tumors displaying significantly greater Id2 expression than either
stage I (P  0.027) or stage III tumors (P  0.033). In addition,
compared with either right-sided or rectal tumors, nuclear Id3 staining
was significantly higher in left-sided tumors (P  0.049; P  0.007;
Table 1). We noted no significant increase in staining of any of the
three Id proteins in 17 colorectal adenomas (data not shown).
Id protein Immunoreactivity Correlates with p53 Immunore-
activity and Mitotic Index in Colorectal Tumors. Using the DOH7
anti-p53 antibody, we found that increased staining is a reliable
marker of mutant p53 protein that possesses a higher stability than
wild type (40). Mutational loss of p53 function is a common event in
colorectal tumorigenesis (40). As shown in Table 2, we found a
statistically significant correlation between Id and p53 immunoreac-
tivities. For Id1, Id2, and Id3, the proportion of tumor cells that were
positive for Id protein correlated with both the proportion of p53-
positive cells and with the total p53 staining. In the case of Id2, this
correlation extended to the total staining pattern for this Id protein.
Both the proportion of Id-positive cells and the total Id staining was
correlated with mitotic index for Id1 and to a lesser extent for Id2, but
not for Id3 (Table 2).
Because the correlation between loss of p53 function, as reflected
by increased immunoreactivity, and Id expression was so striking, we
determined whether loss of p53 function in isolation might influence
Id protein expression levels by an analysis of intestinal epithelium in
p53/ mice. As shown in Fig. 3, intestinal crypts from p53/
mice displayed a higher level of expression of all three Id proteins
Fig. 2. Id protein expression levels in normal mucosa and tumor tissue from patients
with colonic adenocarcinoma. Scatter plots are shown for immunoreactivity of mucosa
and tumor specimens for the patient series. For Id3, the data for cytoplasmic (Id3-C) and
nuclear staining (Id3-N) are shown separately. The immunoreactivity score represents the
total score (TS) which was taken as the product of the intensity score (INT) and the score
for the proportion (PROP) of immunoreactive cells within the specimen. Solid horizontal
lines, mean values. Three mucosal specimens (A, B, and C) displayed consistently
elevated levels of Id immunoreactivity.
Table 1 Id staining in human colorectal adenocarcinomas
Values represent the mean  SE of TS values for Ids 1, 2, and 3 for tumors grouped according to Jass stage and site of lesion.
Id1 Id2 Id3-nuclear Id3-cytoplasmic
Normal Tumor Normal Tumor Normal Tumor Normal Tumor
Jass stage
I (n  11) 1.6  0.6 5.5  0.8 1.4  0.4 5.4  0.7 1.2  0.4 1.7  0.6 0.2  0.1 2.1  0.6
II (n  6) 1.7  0.5 6.7  1.2 1.3  0.3 7.4  1.3 0.8  0.2 2.8  0.4 0.2  0.1 3.1  0.8
III (n  10) 2.0  0.7 5.7  0.7 1.6  0.3 5.7  0.6 1.5  0.4 2.5  0.6 0.8  0.3 2.0  0.6
IVa (n  7) 1.7  0.7 6.6  0.3 4.8  3.0 7.7  0.4b 1.1  0.2 2.9  0.9 0.3  0.1 1.8  0.3
Site
Right (n  9) 1.2  0.3 4.6  0.9 1.4  0.3 5.3  0.9 1.4  0.3 2.0  0.7 0.6  0.2 1.3  0.3
Left (n  12) 1.8  0.6 7.0  0.4 3.4  1.9 7.4  0.5 1.6  0.4 3.5  0.6b 0.4  0.2 2.6  0.5
Rectum (n  13) 2.0  0.6 5.9  0.7 1.6  0.5 6.0  0.7 0.8  0.2 1.6  0.4 0.2  0.1 2.4  0.6
a All of the Jass stage 4 tumors were T4N2–4M0 (TNM staging), Dukes stage C1.
b Subgroups with significantly elevated Id expression relative to other subgroups. These are: (a) Id2 TS for Jass IV Id2 TS Jass I and III at P 0.027 and P 0.033, respectively;
and (b) Id3-nuclear TS for left-sided tumors  Id3-nuclear TS for both right-sided and rectal tumors, at P  0.049 and P  0.007, respectively (Mann-Whitney test).
Table 2 Spearman correlation coefficients for relationships between Id expression, p53
status, and mitotic index in the human colorectal adenocarcinomasa
p53 PROPb p53 TS
Mitotic
index
Id1 0.457 0.517 0.59
PROP (P  0.007) (P  0.002) (P  0.005)
TS 0.173 0.248 0.556
(P  0.008)
Id2 0.41 0.462 0.444
PROP (P  0.016) (P  0.006) (P  0.044)
TS 0.331 0.4 0.447
(P  0.019) (P  0.042)
Id3-C 0.366 0.411 0.341
PROP (P  0.033) (P  0.016)
TS 0.251 0.317 0.312
a Bold figures indicate a significant correlation, at P  0.05.
b PROP, proportion of cells stained; TS, total score; C, cytoplasmic immunoreactivity.
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when compared with wild type. Intriguingly, for Id3, there was also a
marked change in subcellular distribution associated with p53/
crypts, with strong cytoplasmic immunoreactivity in cells at the top of
the crypt and at the crypt-villus junction. No significant elevation of
Id protein expression was observed in p53/mice (data not shown).
Id Protein Expression Is Deregulated in Mouse Adenocarcino-
mas. To investigate the generality of elevated Id protein expression as
a marker of intestinal epithelial tumorigenesis, we extended the anal-
ysis to the Min/ mouse model of tumorigenesis. This mouse strain
develops spontaneous tumors of the intestinal epithelium (35). Tumor
material and matched normal tissue was investigated in six mice. As
shown in Fig. 4, increased expression of Id1–3 was evident in both
small cystic adenomas and in larger tumor masses. No expression of
Id4 was detectable in either normal or malignant mouse intestinal
epithelium (data not shown). The pattern of Id staining was essentially
invariant among different mouse tumors.
Suppression of Adenocarcinoma Cell Proliferation by Anti-
sense Id Oligonucleotides. We next investigated the requirement of
Id protein expression for the proliferation of epithelial adenocarci-
noma cells. As a model, we used two well-characterized human
adenocarcinoma cell lines, HCLO (32) and LS147T (33). As with
primary tumors, both of these cell lines expressed abundant Id1, Id2,
and Id3 protein but were negative for Id4 (Fig. 5). Fig. 6A shows that
the incubation of both of the cell lines with antisense oligonucleotides
specific for Id1, Id2, and Id3 resulted in a dose-dependent suppression
of cell growth as assessed by the percentage of cells in S phase of the
cell cycle. Neither control, sense oligonucleotide, or carrier buffer had
any discernible affect on cell growth (Fig. 6A). As shown in Fig. 6B,
antisense inhibition of cell growth was accompanied by a modest
reduction of expression of one or more of the Id proteins in each cell
line. These observations are consistent with previous studies using
antisense Id oligonucleotides in other cell types (14, 16, 25) and
suggest that cell growth can be attenuated by only a modest reduction
in the level of the cellular Id protein level.
Suppression of Adenocarcinoma Cell Proliferation by bHLH
Protein. The HCLO and LS147T cell lines were used to investigate
the importance of Id-bHLH protein interactions in supporting the
proliferation of adenocarcinoma cells. Of the known bHLH E proteins
(the preferred heterodimerization partners for Id proteins) only the
E2A-encoded proteins, E47/E12 are known to be abundantly ex-
pressed in epithelial cell lineages (Refs. 19, 23; data not shown). As
shown in Fig. 7A, only 50% of the intracellular Id protein is
associated with E2A protein in coimmunoprecipitates prepared from
exponentially growing cultures of the two tumor lines (compare
Western analysis of immune supernatant and immunoprecipitate lanes
from cells transfected with control, pcDNA3 vector, in Fig. 7A).
When cells were transfected with vector expressing E47, a greater
proportion of each Id protein could be immunoprecipitated with the
anti-E2A antibody (Fig. 7A). However, only 5–10% of the cells in
these transiently transfected populations expressed the exogenous E47
protein (data not shown). Therefore, to show more definitively that the
pool of endogenous Id proteins is associated with the transfected E47
protein, we exploited the fact that Id proteins lack a nuclear localiza-
tion signal and are found predominantly in the cytoplasm/perinuclear
region of many cell types, whereas their bHLH partners such as E47
possess a strong nuclear localization signal and are usually localized
exclusively to the nucleus (37). As shown in Fig. 7B, whereas cells not
expressing exogenous E47 protein displayed a diffuse, cytoplasmic
staining of Id3, those cells expressing exogenous E47 exhibited strong
nuclear staining of Id3. Similar results were obtained for Id1 and Id2
Fig. 4. Expression of Id proteins in normal and tumor tissue from Min/ intestinal
epithelium. In A, immunostaining of “normal” epithelium, cystic tumors, and adenomas is
shown for comparison. In B, Western analysis of immunoprecipitates of Id proteins from
normal mouse intestinal epithelium (N) are compared with a representative mouse ade-
noma (T) that was excised from the epithelium.
Fig. 3. Expression of Id proteins in intestinal epithelia from wild-type and p53/
mice. A, immunostaining of Id protein in sections from wild-type (Wt) or p53-null
(p53/) mice. B, Western analysis of immunoprecipitates of Id protein from intestinal
epithelia of Wt and p53/mice. Cell lysates were obtained from intestinal epithelial cell
preparations processed by the Weiser method (see “Materials and Methods”).
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(data not shown). This colocalization of E47 and Id proteins in the
nuclei of E47-transfected cells is consistent with sequestration of
cellular pools of Id protein as an Id-E47 heterodimer. To determine
whether such cells expressing a functional excess of bHLH E protein
over Id protein are affected in their proliferative capacity, we assessed
BrdUrd incorporation in transiently transfected cells by using the
LacZ gene as a marker. As shown in Fig. 7C, the ability of E47
overexpressing cells to progress into the S phase of the cell cycle was
suppressed by 80–90% in both cell lines.
These experiments suggest that the proliferative capacity of intes-
tinal adenocarcinoma cell lines can be modulated by perturbing the
balance of cellular pools of Id and bHLH proteins; an excess of Id
protein supports proliferation, whereas an excess of bHLH protein,
with accompanying loss of “free” Id protein, results in cell cycle
arrest. However, it could be argued that the E47-induced growth arrest
observed in these experiments is as much a consequence of the high
levels of exogenous E47 protein as the sequestration of cellular pools
of Id protein into a heterodimer state in transfected cells. To overcome
this caveat, we designed an attenuated mutant of E47 in which the
region imparting transcriptional transactivation function (NH2-termi-
nal to the HLH domain) is deleted and the basic DNA binding domain
is mutated to abolish DNA binding ability as described previously by
Chakraborty et al. (39). The structure of this mutant (antagonist,
aHLH protein), which also possesses a myc epitope tag at the NH2
terminus, is depicted in Fig. 8A. The HLH domain of the aHLH
protein is preserved so that it should still be able to form heterodimers.
However, because bHLH-bHLH dimerization is stabilized by DNA
binding, the mutant should preferentially dimerize with Id protein [the
stabilization of which does not require DNA binding (see Ref. 1)]. As
shown in Fig. 8B, the aHLH protein could be detected in transfected
cells by Western blotting using E47 antiserum after immunoprecipi-
tation with 9E10 antibody, specific for the myc epitope tag present on
the aHLH protein. However, as shown in Fig. 8C, when a construct
encoding wild-type E47 was cotransfected with aHLH vector, none of
the E47 protein was coimmunoprecipitated with the aHLH protein;
essentially all of the E47 protein remained in the immune supernatant
(Fig. 8C). Cells were then transfected with the aHLH construct, and
the extent of association with either endogenous or exogenous (co-
transfected) Id protein was evaluated by immunoprecipitation with
anti-myc tag antibody followed by Western blotting with antisera for
each of the three Id proteins (Fig. 8D). Somewhat surprisingly, for
both the endogenous and exogenous Id proteins, only Id1 and not Id2
nor Id3 was found to associate with the aHLH protein. Despite this
altered dimerization potential of the aHLH protein (which presumably
arises as a consequence of removal of the NH2-terminal region and or
mutation of the basic, DNA-binding domain), adenocarcinoma cells
transiently transfected with this construct still displayed an apprecia-
ble suppression in proliferative capacity (3- to 4-fold) as assessed
from the percentage of cells in S phase of the cell cycle (Fig. 8E). This
observation is consistent with data obtained by antisense oligonucleo-
tide blockade (Fig. 6) in showing that a partial reduction of the cell’s
complement of Id protein impairs proliferation. Taken together, the
data strongly imply that proliferation of adenocarcinoma cells is
dependent on the elevated expression levels of Id protein observed in
these tumor cells.
DISCUSSION
A substantial body of evidence from experimental model systems
now supports a role for Id proteins in tumorigenesis mechanisms
(reviewed in Refs. 2, 3). However, studies on primary human tumors
have shown that deregulated expression of Id genes is not apparently
Fig. 5. Id protein expression in human colonic adenocarcinoma cell lines. Western
analysis for each of the four Id proteins was performed on immunoprecipitates of Id
proteins prepared from the two cell lines, HCLO and LS174T. As positive controls, lysates
were prepared and analyzed in parallel from Cos7 cells transiently transfected with
pcDNA3 expression vectors encoding each Id protein.
Fig. 6. Inhibition of adenocarcinoma cell proliferation by Id antisense oligonucleotides.
In A, cells were seeded in chamber slides and treated with the indicated concentrations of
an equimolar mixture of either sense or antisense Id1, Id2, and Id3 oligonucleotide. An
additional control of treatment of cells with carrier buffer was also included. After 17 h,
cells were pulsed with BrdUrd for 2 h. The percentage of cells in S phase was determined
by scoring BrdUrd-positive cells detected by immunostaining. The data shown are from
two experiments, each performed in triplicate. B, lysates from cells treated with a 10-M
mixture of either sense or antisense oligonucleotides for Id1, Id2, and Id3 were analyzed
by Western blotting for Id protein expression. Bottom panel, a representative Coomassie
Blue-stained gel to show equivalence of protein loading.
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a universal feature of malignancy; most primary leukemias, for ex-
ample, do not display abnormalities in Id expression (41, 42). Among
solid tumor types, the published data are still relatively limited (Refs.
24–28; reviewed in Refs. 2, 3). The present study represents the first
systematic survey of Id protein expression in colorectal cancer and
also addresses the relationship with histopathological and other fea-
tures of disease. Our studies revealed that deregulated expression of
Id1–3, but not of Id4, is a consistent feature of both human and mouse
Fig. 7. Suppression of epithelial tumor cell proliferation by E2A protein. In A, both
human colorectal cell lines, HCLO and LS174T, were transiently transfected either with
control (empty vector, pcDNA3) or with vector expressing the E2A bHLH protein, E47
(pcDNA3-E47). Lysates were prepared and subjected to immunoprecipitation with anti-
E47 antibody followed by Western analysis with anti-E47 antibody (top panel). For
pcDNA3 transfected cells, the immune supernatant (containing Id protein not associated
with endogenous E protein) was subjected to immunoprecipitation with each of the Id
antibodies (immune sup). An equivalent proportion of E47 immunoprecipitate (containing
Id protein associated with endogenous E protein) was redissolved and similarly immu-
noprecipitated with each Id antibody (immune ppt) for comparison as shown in the bottom
panel. For pcDNA3 transfected cells, E47 immunoprecipitates were redissolved and
subjected to immunoprecipitation with anti-Id antibodies to show the association with
endogenous Id protein. Immunoprecipitates were subjected to Western analysis with each
of the anti-Id antibodies indicated. Additional control samples from Cos7 cells, transiently
transfected with Id (or E47) constructs were used to confirm the identities of bands as
indicated (see Fig. 5). In B, HCLO cells, transiently transfected with the E47 expression
vector, were fixed and immunostained for Id3 and E47 proteins, then counterstained with
DAPI. The representative field of view shows colocalization of Id3 and E47 proteins in
the nucleus in cells expressing the exogenous E47 protein. In C, the HCLO and LS174T
cell lines were transiently cotransfected with LacZ vector, together with either empty
control vector, pcDNA3, or with vector expressing the E2A bHLH protein, E47
(pcDNA3-E47) as indicated. Twenty-four h later, the cells were pulsed for 2 h with
BrdUrd, fixed, and then immunostained for codetection of LacZ and incorporated BrdUrd.
The percentage of cells in S phase was evaluated by scoring a minimum of 200 cells from
both LacZ-positive and LacZ-negative populations in each transfection. The data were
taken from two experiments.
Fig. 8. Suppression of epithelial tumor cell proliferation by the aHLH protein. A,
structure of the aHLH mutant construct derived from E47. In B, cells were transfected
with either empty vector, pcDNA3, or with pcDNA3-aHLH; and lysates were subjected
to immunoprecipitation with 9E10 antibody, specific for the myc-epitope tag. Immuno-
precipitates (Immune ppt) were analyzed by Western blotting using E47 antibody. Sam-
ples of total cell protein from an equivalent number of transfected cells were analyzed as
a control. kDa, Mr in thousands. In C, cells were cotransfected with the aHLH expression
construct and pcDNA3-E47, and lysates were analyzed by immunoprecipitation for the
myc epitope tag [immunoprecipitate (Immune ppt) and immune supernatant (Immune sup)
are compared]. E47 antibody was used in Western blot analysis. In D, cells were
transfected either with pcDNA3-aHLH or with pcDNA3-aHLH plus constructs expressing
each of the Id proteins as indicated. Equivalent cell numbers were analyzed by Western
blotting for each Id protein, using either whole cell protein or cell lysate that had been
immunoprecipitated with 9E10 antibody, specific for the myc tag on the aHLH protein. In
E, cells were cotransfected with LacZ vector, together either with control empty vector,
pcDNA3, or with pcDNA3-aHLH, as indicated. Twenty-four h later, the cells were pulsed
for 2 h with BrdUrd, fixed, and then immunostained for detection of LacZ and incorpo-
rated BrdUrd. The percentage of cells in S phase was evaluated by scoring a minimum of
200 cells from both LacZ-positive and LacZ-negative populations in each transfection.
The data were taken from two experiments.
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intestinal epithelial tumors. Interestingly, no significant elevation of
Id expression was seen in human colorectal adenomas, which implies
that up-regulation of Id expression levels occurs as a relatively late
event during tumorigenesis of intestinal epithelium, at least in humans.
In most patients, we found that Id protein levels in normal mucosa
were low and fell within a narrow range. However, in three patients,
who also displayed particularly high Id expression levels in tumor
tissue, the mucosal expression levels were also consistently high.
Evaluation of histopathological and other data revealed no obvious
distinguishing features in these patients. However, because expression
of Id genes is well documented to be responsive to a plethora of
growth factor signals (1), it is possible that paracrine mechanisms
involving factors secreted by tumor tissue might explain the elevated
Id expression in the normal mucosa of these patients. This possibility
may have relevance to tumorigenesis mechanisms because Id proteins
are involved in vascularization and tumor invasiveness (19, 20).
Evaluation of the patient series as a whole revealed several signif-
icant associations with histopathological and other features of tumors.
Of these, the correlation with mitotic index and p53 expression levels
was highly significant. The correlation between mitotic index and
expression of Id1, and to a lesser extent with expression of Id2, may
well reflect the ability of Id proteins to enhance cellular proliferation
when experimentally overexpressed in a number of cell types (1),
including cells of epithelial lineage (Ref. 19).4 We were able to show
that the correlation between expression of all three Id proteins and p53
expression (as a marker of mutational modulation of p53 function) can
be explained by a direct causal relationship, because loss of p53
function in p53-null mice led to up-regulation of Id protein levels in
otherwise normal mucosa. It seems likely, therefore, that loss of p53
function represents an important mechanism through which Id protein
expression is deregulated in colonic adenocarcinoma cells.
Expression of Id proteins is known to be regulated through mech-
anisms, as yet poorly understood, that operate at both the transcrip-
tional and translational levels (1). The precise determinants of p53-
dependent (and p53-independent) up-regulation of Id expression in
tumor cells are, therefore, likely to be complex. However, in common
with p53, Id proteins are rapidly up-regulated in response to genotoxic
stress stimuli, and at least one gene target for p53, p21WAF-1/CIP1, is
also reportedly regulated by Id proteins (43). Thus, some cross-talk
between the p53 and Id signaling pathways might well be expected.
A major pathway of cell-fate determination is regulated by a critical
balance between the opposing functions of bHLH and Id proteins
(1–3). Several studies have shown that abrogation of Id function by
antisense oligonucleotide blockade or by microinjection of antibodies
(resulting in a functional excess of the cell’s compliment of bHLH
protein) results in an arrest in the G1-to-S phase transition of the cell
cycle and to the inhibition of cellular proliferation (14–16). Antisense
Id oligonucleotide blockade similarly led to the suppression of pro-
liferation of adenocarcinoma cells in the present study. By enforced
expression of the bHLH protein, E47, which is known to form stable
heterodimers with Id proteins (5), we showed by both coimmunopre-
cipitation and immunofluorescence colocalization studies that essen-
tially all of the cellular pools of Id protein become associated with the
E47 protein in transfected cells. Under these conditions of experimen-
tally manipulated bHLH protein excess, cellular proliferation was
significantly suppressed. Moreover, we found that the sequestration of
cellular pools of Id1 by using an antagonist HLH protein that was
defective in DNA binding and transactivation function also resulted in
the suppression of adenocarcinoma cell proliferation. Thus, we infer
that a functional excess of Id protein is necessary to support the
proliferation of these tumor cells. Given the known oncogenic prop-
erties of Id proteins established in various experimental models (2, 11,
17–22), and the observation that targeted transgene expression of Id1
in murine intestinal epithelium is associated with tumor induction
(23), it is likely that the up-regulated expression of Id proteins seen in
primary human colorectal tumors is a major determinant of tumori-
genesis of the colonic epithelium.
Mutations in a number of onco/tumor suppressor genes such as
APC, DCC, K-ras, and p53 are involved in tumorigenesis of colonic
epithelium (44). Perturbations in the expression of several important
regulators of the cell cycle such as cyclin D3 (45), Cdk2 (46),
p21WAF-1/CIP1 (47) and p27Kip1 (48) have also been described in this
tumor type. However, the mechanisms through which primary genetic
lesions ultimately modulate the expression of these cell cycle regula-
tors and the role of the latter in colorectal tumorigenesis is not known.
Our data show that deregulated expression of Id protein family mem-
bers is likely to be an important determinant in colorectal tumorigen-
esis and arises at least in part through a loss of p53 function.
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